- Home
- FUTU vs BNTX Comparison
FUTU vs BNTX Comparison
Compare FUTU & BNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FUTU | BNTX |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | Hong Kong | Germany |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.1B | 24.8B |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | FUTU | BNTX |
|---|---|---|
| Price | $171.11 | $94.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $208.60 | $137.40 |
| AVG Volume (30 Days) | ★ 1.5M | 1.3M |
| Earning Date | 11-18-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 119.17 | N/A |
| EPS | ★ 8.95 | N/A |
| Revenue | $2,442,834,991.00 | ★ $3,698,814,972.00 |
| Revenue This Year | $87.24 | $2.36 |
| Revenue Next Year | $13.85 | N/A |
| P/E Ratio | $19.17 | ★ N/A |
| Revenue Growth | ★ 87.15 | 3.70 |
| 52 Week Low | $70.60 | $81.20 |
| 52 Week High | $202.53 | $129.27 |
Technical Indicators
Market Signals| Indicator | FUTU | BNTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.34 | 38.15 |
| Support Level | $166.60 | $94.52 |
| Resistance Level | $175.77 | $97.35 |
| Average True Range (ATR) | 5.39 | 2.72 |
| MACD | 0.59 | -0.24 |
| Stochastic Oscillator | 51.53 | 8.21 |
Price Performance
Historical ComparisonAbout FUTU Futu Holdings Limited
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and the United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services, and interest income.
About BNTX BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.